CRUSADE Bleeding Risk Score Calculator
Bleeding risk assessment
Enter baseline findings at presentation to estimate in-hospital major bleeding risk in NSTE-ACS.
—Score
About the CRUSADE Bleeding Score
The CRUSADE Bleeding Score estimates in-hospital major bleeding risk in patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI). It uses eight baseline clinical variables and was derived and validated in a large multicenter registry.
Scoring criteria
| Variable | Criterion | Points |
|---|---|---|
| Hematocrit (%) | <31 / 31–33.9 / 34–36.9 / 37–39.9 / ≥40 | 9 / 7 / 3 / 2 / 0 |
| Creatinine clearance (mL/min) | ≤15 / >15–30 / >30–60 / >60–90 / >90–120 / >120 | 39 / 35 / 28 / 17 / 7 / 0 |
| Heart rate (beats/min) | ≤70 / 71–80 / 81–90 / 91–100 / 101–110 / 111–120 / ≥121 | 0 / 1 / 3 / 6 / 8 / 10 / 11 |
| Female sex | Female | 8 |
| Heart failure signs | Present at presentation | 7 |
| Prior vascular disease | Prior stroke or peripheral arterial disease | 6 |
| Diabetes mellitus | Present | 6 |
| Systolic blood pressure (mmHg) | ≤90 / 91–100 / 101–120 / 121–180 / 181–200 / ≥201 | 10 / 8 / 5 / 1 / 3 / 5 |
Risk categories in the original cohort
| Total score | Risk group | In-hospital major bleeding rate |
|---|---|---|
| 1–20 | Very low | 3.1% |
| 21–30 | Low | 5.5% |
| 31–40 | Moderate | 8.6% |
| 41–50 | High | 11.9% |
| >50 | Very high | 19.5% |
These categories and rates reflect the original CRUSADE cohort and may not exactly represent contemporary local populations or an individual patient's risk.
References
Subherwal S, Bach RG, Chen AY, et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE Bleeding Score. Circulation. 2009;119(14):1873–1882.DOI: 10.1161/CIRCULATIONAHA.108.828541PMID: 19332461
Clinical use and limitations
- Developed for in-hospital major bleeding risk estimation in NSTEMI; applicability to other ACS populations should be considered carefully.
- Creatinine clearance in the original model was estimated using Cockcroft–Gault. Do not substitute eGFR without considering the methodological difference.
- The score is not a stand-alone treatment rule and should not delay indicated ACS care.
- Use clinical judgement and current local guidelines when choosing antithrombotic therapy, dosing, invasive strategy, and monitoring.
Clinical disclaimer: This calculator is an educational and clinical decision-support aid, not a substitute for clinician judgement. Confirm input data and assess the complete clinical context, including ischemic risk, active bleeding, thrombocytopenia, anticoagulant use, renal function, and planned procedures. Do not use the CRUSADE score alone to withhold or delay indicated treatment.
PERSONAL WORKSPACE
Clinical notes
Document key findings and keep a structured record for your own reference.
Private by design. Notes are stored in this browser on this device only. They are not uploaded to Appcardio.
Export or share this note
PERSONAL WORKSPACE
My notes
Review, edit, or remove notes saved in this browser.
Stored locally on this device
QUALITY & SAFETY
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.
Please describe the issue clearly. For calculation concerns, include the input values and expected result where possible.